Background {#Sec1}
==========

The early results of the first adjuvant Milan trial were published in 1976 \[[@CR1]\], and showed a clear benefit from 4-weekly oral cyclophosphamide on days 1 to 14 combined with intravenous methotrexate and fluorouracil on days 1 and 8 (CMF). The Milan trial included patients with high-risk (node-positive) breast cancer who were randomized after mastectomy; none of whom received radiotherapy or endocrine treatment. Several cooperative groups, including the Danish Breast Cancer Group (DBCG), initiated trials to explore the results from the pivotal Milan trial. DBCG 77B included premenopausal patients with high-risk breast cancer who after mastectomy and radiotherapy and without endocrine treatment were randomized to observation, levamisole, single-agent cyclophosphamide, or CMF. Results showed a similar benefit from oral cyclophosphamide and CMF, and the survival benefit was maintained after 25 years of follow up \[[@CR2]\]. Due to the results of these and other early clinical trials, adjuvant chemotherapy has been considered a standard in premenopausal patients with node-positive breast cancer since the National Institutes of Health Consensus Conference in 1980 \[[@CR3]\]. Subsequent meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) have demonstrated that the relative benefit of CMF was largely independent of patient characteristics, nodal status and other tumor features available for analysis, and also independent of the use of concomitant tamoxifen. Furthermore, in the EBCTCG analysis an additional incremental benefit was shown from adding an anthracycline to CMF, from substituting methotrexate with doxorubicin or epirubicin, and from giving taxanes concurrently or in sequence with anthracyclines \[[@CR4], [@CR5]\].

Since intrinsic molecular subtypes were first described more than 15 years ago, their prognostic ability has repeatedly been demonstrated in early breast cancer \[[@CR6]\]. However, few attempts have been made to explore the ability of these subtypes to predict benefit of chemotherapy. The prediction analysis of microarray 50 (PAM50) gene set has become a standard for identifying intrinsic subtypes from RNA expression measurements and its predictive abilities have been evaluated in the Canadian MA.5 trial comparing adjuvant cyclophosphamide, epirubicin, and fluoroucil (CEF) to CMF in patients with early breast cancer. The human epidermal growth factor receptor 2 (Her2)-enriched subtype was associated with a benefit from the anthracycline-containing chemotherapy arm while no significant differences between arms were shown for patients with basal-like, luminal A or luminal B breast cancers \[[@CR7]\]. Additionally, a high 21-gene recurrence score (OncotypeDx) has been associated with benefit from addition of cyclophosphamide, adriamycin, and fluorouracil (CAF) to tamoxifen \[[@CR8]\] in high-risk node-positive disease, suggesting that not all patients with high-risk early breast cancer derive a similar benefit from adjuvant chemotherapy.

The PAM50 gene signature has been developed into a clinical test, the Prosigna gene signature assay, validated to estimate the prognosis for postmenopausal patients with estrogen receptor (ER)+ early-stage breast cancer \[[@CR9], [@CR10]\]. In the DBCG 77B trial we randomized premenopausal patients with high-risk breast cancer to cyclophosphamide-based chemotherapy against no systemic treatment, and the two primary co-objectives of this study were to evaluate the predictive ability of the PAM50-based Prosigna risk of recurrence (ROR) score and intrinsic subtypes.

Methods {#Sec2}
=======

Details on DBCG 77B have been published previously \[[@CR2]\]. In brief, this was an open-label randomized phase III trial comparing, in the adjuvant setting, radiotherapy alone (control), radiotherapy plus 2.5 mg/kg/body weight of levamisole on 2 days consecutively each week for 48 weeks, radiotherapy plus 12 cycles of single-agent cyclophosphamide (C) 130 mg/m^2^ orally on days 1--14 every 4 weeks, or radiotherapy plus 12 cycles of CMF (cyclophosphamide 80 mg/m^2^ orally on days 1--14, methotrexate 30 mg/m^2^ intravenously on days 1 and 8, and 5-fluorouracil 500 mg/m^2^ intravenously on days 1 and 8) every 4 weeks. Patients were eligible for DBCG 77B if they were without distant metastasis, were premenopausal, and had either positive lymph nodes, tumors \> 5 cm, and/or invasion of the deep fascia. The DBCG prepared the original 77B trial and its biological sub-studies have previously been described in detail \[[@CR2], [@CR11]\]. The Biomedical Research Ethics of the Danish Capital Region approved the protocol (H-15012740).

Central assessment of Prosigna {#Sec3}
------------------------------

Formalin-fixed, paraffin-embedded tumor blocks (FFPE) from primary excisional surgery specimens were collected at the Department of Pathology, Zealand University Hospital. RNA extraction and Prosigna testing were performed according to standard operating procedures \[[@CR9]\] by investigators blinded to clinical outcome. Prosigna results were transferred to the data manager at Nanostring, who while remaining blinded to clinical data, prepared the Prosigna ROR and intrinsic subtype analysis data set. This was forwarded to the DBCG statistical office for merging with clinical data and to execute the prespecified statistical analysis plan. ROR cut offs for analysis of the combined study population (including ER+/− and Her2+/−) were prespecified in terms of the observed ROR score distribution tertiles within the study population (8--51 (low), 52--71 (intermediate), and 72--100 (high)) and were independent of nodal status.

The age of the FFPE tissue blocks resulted in decreased RNA quality compared with previous studies performed by the DBCG. In order to increase power for the exploratory analysis in the ER+/Her2- population, the Prosigna test quality control criteria for RNA quality was relaxed for this subset.

Statistical methods {#Sec4}
-------------------

A written prespecified statistical analysis plan was finalized prior to data analysis. The statistical analysis was executed by the DBCG statistical office, which was not involved in biomarker data collection. The primary endpoint for this study was disease-free survival (DFS), defined as time from randomization to any first event of invasive ipsilateral or contralateral breast cancer recurrence, local or regional invasive recurrence, distant recurrence, second (non-breast) invasive cancer, or death from any cause. The secondary endpoint was overall survival (OS), defined as time from date of randomization until death from any cause. Survival rates were estimated by the Kaplan-Meier method. Patients treated according to protocol were included. Cox proportional hazards regression models were applied to assess the unadjusted and adjusted hazard ratios (HR). The chemotherapy arms (C + CMF) were analyzed versus no chemotherapy arms (control + levamisole). The multivariate models included age at entry (≤ 40, 41--45, 46--50, and 50 years), tumor size (≤ 2, \> 2 to ≤ 5, and \> 5 cm), lymph node (LN) status (0--3 positive LN, 4--9, 10+ and \< 10 vs 10+ retrieved), histologic type (ductal vs non-ductal), grade (ductal I, II, and III) and treatment regimen. Proportional hazards assumptions were assessed using Schoenfeld residuals and by including a time-dependent component for each covariate. The hazard rates for histologic type and grade were not proportional; therefore, stratification was used. To comply with proportional hazards assumptions about subtypes and ROR score, separate estimates were included according to time since randomization. The Wald test was used to assess heterogeneity. Associations between included and excluded patients and clinico-pathological characteristics (excluding unknowns) were analyzed using the chi-square test. *P* values are two-tailed, unadjusted for number of comparisons. Central review, monitoring, and statistical analyses were done by the DBCG Statistical Office using the SAS 9.4 software program package (SAS Institute, Cary, NC, USA).

Results {#Sec5}
=======

The DBCG 77B trial enrolled 1146 patients, among whom 1072 received treatment as allocated by randomization (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Tumor blocks were available from 649 patients, and 623 blocks contained sufficient invasive breast cancer tissue for RNA extraction. The Prosigna assay was successful in 487 patients, of which 460 were treated according to protocol. The assessable 460 patients did differ significantly from the 612 non-assessable patients (*P* \< 0.05) with regard to histologic type (*P* = 0.03) and malignancy grade (*P* = 0.02). Among the 460 patients, 231 (81%) experienced a first event within 10 years. Number of positive lymph nodes, tumor size, age, and treatment regimen were not significantly different in assessable vs non-assessable patients. The treatment effect was similar with an HR favoring chemotherapy for DFS (adjusted HR; 0.55; 95% CI, 0.38 to 0.79; *P* = 0.001) to the effect observed in the original study (HR = 0.60; 95% CI, 0.48 to 0.75). Table [1](#Tab1){ref-type="table"} shows the baseline characteristics according to Prosigna subtype for the 460 patients: 324 patients were included in the exploratory analysis of DFS in the ER+/Her2− patient population.Table 1Patient and tumor characteristics by Prosigna (PAM50) subtypeTotal study setMolecular subtypeLuminal ALuminal BBasal-likeHer2-ECharacteristics*N*%*N*%*N*%*N*%*N*%Number of patients460--1613511827611312026Age  \< 40 years96212314262219312823 40--49 years233519458635325415143 50--59 years131284427292517284134Lymph nodes excised None19485761233 1--3110244226272314232723 4--9268589760675739646554  \> 961414917147112521Lymph node status Negative43916104310161311 1--3 positive2715910666726133546050 4+ positive127283119353017284437 Unknown19485761233Tumor size 0--20 mm132296037363114232218 21--50 mm239527748615230497159  \> 50 mm85182415211813212723 Unknown4100004700Deep fascia invasion Absent3467512779937945748168 Present109243220252115253731 Unknown5121001222Histologic type Ductal carcinoma39385132829984528511092 Lobular carcinoma337161013111233 Other2861175461065 Unknown6121112311Malignancy grade^a^ Grade I6517463515151233 Grade II242628161737422426660 Grade III862254111129564137HR status Positive3297214691112956106554 Negative11425645452855143 Unknown17496113543Systemic treatment Control or levamisole113253723342910163227 C or CMF3477512477847151848873ROR score groups Low (0--51)155341358422142343 Intermediate (52--71)148322616504240663227 High (72--100)157340066567118470*PAM50* prediction analysis of microarray 50, *C* cyclophosphamide, *CMF* cyclophosphamide, methotrexate and fluorouracil, *HR* hormone receptor, *Her2-E* human epidermal growth factor receptor 2-enriched, *ROR* risk of recurrence^a^Ductal carcinomas only

Of the 460 patients included in the primary analyses 61 (13%) were classified as having basal-like, 120 (26%) as Her2-enriched, 161 (35%) as luminal A and 116 (25%) as luminal B breast cancer, reflecting the population including patients with ER+/− and Her2+/− breast cancer.

Prognosis by Prosigna ROR score {#Sec6}
-------------------------------

The continuous ROR score was highly prognostic (unadjusted HR, 1.23; 95% CI, 1.09 to 1.39, *P* \< 0.001 for a 10-point difference) for DFS within the group not treated systemically. For the C/CMF-treated group, the ROR continuous score had a different effect according to follow-up time (0--5 years vs 5+ years) (Fig. [1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"}). The ROR prognosis was statistically significant for the first 5 years for both the C/CMF arm and the no chemotherapy arm, and with no differential effect, whereas after 5 years no prognostic effect was apparent. There was no statistically significant differential effect according to follow-up time in the no chemotherapy arm alone. Including all patients, irrespective of hormone receptor status, the 10-year DFS rates in the untreated group were 62% (95% CI, 43 to 76), 27% (95% CI, 14 to 43) and 27% (95% CI, 15 to 41) for low, intermediate, and high ROR scores, respectively (Fig. [2a](#Fig2){ref-type="fig"}). Comparing intermediate ROR with low-risk ROR for the untreated group, unadjusted HR = 2.66; 95% CI, 1.35 to 5.24, and similarly for the high vs low-risk ROR group HR = 2.73; 95% CI, 1.43 to 5.22. Likewise, the ROR score was prognostic for OS in the untreated group (Fig. [2b](#Fig2){ref-type="fig"}) and the 10-year OS rates were 63% (95% CI, 45 to 76), 38% (95% CI, 22 to 54), and 30% (95% CI, 17 to 43) for low, intermediate, and high ROR scores, respectively.Fig. 1**a** Disease-free survival by continuous risk of recurrence (ROR) score 0--5 years and 5--10 years after randomization, respectively, for patients in the systemically untreated regimen (CT --) and patients in the C/CMF arm (CT +). **b** Overall survival by continuous ROR score for 0--5 years and 5+ years after randomization, respectively. Hazard ratios and corresponding 95% CI for a 10-point difference in continuous ROR score are shownFig. 2**a** Kaplan-Meier estimates of disease-free survival in the 113 patients systemically untreated (-- CT), according to low, intermediate, and high Prosigna risk of recurrence (ROR) scores. **b** Kaplan-Meier estimates of overall survival

Effect of chemotherapy according to the Prosigna ROR score {#Sec7}
----------------------------------------------------------

For the first co-primary objective, we examined the association between the continuous Prosigna ROR score and benefit of chemotherapy in the population including patients with ER+/− and Her2+/− breast cancer. There was no significant effect of the ROR score on treatment; for the continuous ROR score *P*~interaction~ = 0.66 for DFS and *P*~interaction~ = 0.32 for OS, in unadjusted models. The benefit for DFS was significant for both intervals of intermediate (52--71) and high (72--100) Prosigna ROR scores, whereas there was a smaller, non-significant benefit for low (0--51) ROR scores, although interactions between ROR score groups and benefit of chemotherapy were not statistically significant (Table [2](#Tab2){ref-type="table"} for unadjusted results) (*P*~interaction~ = 0.47), also true for OS (P~interaction~ = 0.24). The HR for impact of the continuous ROR as the impact of the predefined intervals remained largely unchanged following adjustment for patients and tumor characteristics (Fig. [3a](#Fig3){ref-type="fig"} and [b](#Fig3){ref-type="fig"}).Table 2Unadjusted HR estimates of the treatment effect for DFS and OS according to Prosigna ROR scores and subtypeDFSOSHR(95% CI)P~interaction~HR(95% CI)*P* ~interaction~ROR score0.470.24 Low tertile0.79(0.42--1.47)1.09(0.70--1.71) Intermediate tertile0.49(0.30--0.79)0.75(0.50--1.13) High tertile0.64(0.42--0.98)0.66(0.46--0.96)Subtype0.0030.04 Luminal A0.64(0.36--1.14)0.96(0.62--1.48) Luminal B0.47(0.28--0.77)0.51(0.33--0.77) Basal-like0.19(0.09--0.40)0.52(0.24--1.12) Her2-enriched1.04(0.62--1.75)1.10(0.71--1.71)*DFS* disease-free survival, *OS* overall survival, *HR* hazard ratio, *ROR* risk of recurrence, *95% CI* 95% confidence interval, *P*~*interaction*~ *P* derived from a Wald test for heterogeneity, *Her2* human epidermal growth factor receptor 2Fig. 3Forest plots illustrate proportional hazard models for disease-free survival (**a**) and overall survival (**b**) overall and according to intrinsic cancer subtype and risk of recurrence (ROR) score, respectively. Hazard ratios refer to adjusted estimates obtained in the multivariate analysis. *P* values are for test of heterogeneity of treatment effect. Boxes represent the weight of data for each subgroup relative to the total data. Pt.s, patients; Lum, luminal; HER2E, human epidermal growth factor receptor 2-enriched

Prosigna has been validated and is indicated for use in ER+, Her2− disease only, therefore, an underpowered but planned exploratory analysis of DFS in the ER+, Her2- subset was also executed using the risk groups defined by the commercial cut point of low-risk ROR ≤ 40. A benefit from chemotherapy was observed in the high-risk group (HR = 0.48, 95% CI, 0.33 to 0.69) while no benefit was demonstrated in the low-risk group (HR = 1.13, 95% CI, 0.42 to 3.07); however, no there was no statistically significant interaction between ROR risk groups and treatment effect (unadjusted *P*~interaction~ = 0.11) (Additional file [2](#MOESM2){ref-type="media"}: Figure S2) and (adjusted *P*~interaction~ = 0.10).

Effect of chemotherapy for Prosigna intrinsic subtype groups {#Sec8}
------------------------------------------------------------

For the second co-primary objective, we examined the association between Prosigna intrinsic subtypes and benefit of chemotherapy. A significant interaction was observed between Prosigna subtype and treatment (Table [2](#Tab2){ref-type="table"}) for DFS (*P*~interaction~ = 0.003) and OS (*P*~interaction~ = 0.04), with the subtypes included separately. Statistically significant interactions between the Prosigna subtypes and treatment remained after multivariate adjustment both for DFS (Fig. [3a](#Fig3){ref-type="fig"}) and OS (Fig. [3b](#Fig3){ref-type="fig"}). Patients with a basal-like subtype of breast cancer had a pronounced benefit from cyclophosphamide-based adjuvant chemotherapy (unadjusted HR, 0.19; 95% CI, 0.09 to 0.40), and a marked benefit was also obtained by those with the luminal B subtype (unadjusted HR, 0.47; 95% CI, 0.28 to 0.77) (Fig. [4](#Fig4){ref-type="fig"}). While there was significant benefit from chemotherapy on DFS in both the subgroups with basal-like and luminal B subtype breast cancer, there was no effect in women with Her2-enriched tumors, and a less pronounced effect in those with luminal A tumors (*P*~adjusted~ = 0.001). The benefit was not significantly different in patients with the luminal A subtype from those with the luminal B subtype (*P*~adjusted~ = 0.52) or from those with non-Luminal A subtype tumors combined (*P*~adjusted~ = 0.87). For OS the corresponding figures are *P*~adjusted~ = 0.09 and *P*~adjusted~ = 0.32.Fig. 4Kaplan-Meier estimates of disease-free survival in patients with luminal (Lum) A (**a**), luminal B (**b**), basal-like (**c**), and human epidermal growth factor receptor 2-enriched (HER2-E) (**d**) breast cancer in the systemically untreated arm (--CT) and in the cyclophosphamide/cyclophosphamide, methotrexate and fluorouracil arm (+CT)

Discussion {#Sec9}
==========

Premenopausal patients with high-risk breast cancer are generally recommended chemotherapy, but our study suggests that patients with tumors from different intrinsic molecular subtypes do not benefit equally from cyclophosphamide or CMF-based adjuvant chemotherapy. When considering a heterogeneous population of patients with ER+/− and Her2+/− disease, the continuous Prosigna ROR score was shown to be significantly associated with prognosis. The Prosigna ROR score was not significantly predictive of treatment effect in a population combining ER+/− and Her2+/− patients. However, the biology of these disease subtypes is dramatically different and it is not unexpected that a score developed to predict disease recurrence in ER+ Her2− patients does not predict benefit from chemotherapy across all ER+/− and Her2+/− patients. By focusing on the more homogenous population of ER+, Her2− patients we did observe a benefit from chemotherapy in the high-risk population and no benefit in the low-risk population though similarly, we found no statistically significant heterogeneity of treatment effect according to ROR score. This subset analysis was hindered by the limited number of patients included, especially for the group not treated with chemotherapy.

More crucially, a significantly different and clinically relevant benefit was obtained based on the major intrinsic subtypes as assigned by Prosigna. The use of cyclophosphamide-based chemotherapy in patients with basal-like breast cancer was associated with an 86% relative reduction in DFS events and a 56% relative reduction in mortality. Patients with luminal B disease also had a statistically significant benefit from chemotherapy, albeit to a lesser degree (39% reduction in DFS events and in mortality). In contrast, patients with tumors of the Her2-enriched subtype and luminal A subtype obtained no statistically measurable benefit. The gain obtained by patients with a luminal A subtype however, did not significantly differ from those with a luminal B nor from those with a non-luminal A subtype taken together.

This heterogeneity in benefit from chemotherapy according to the intrinsic subtypes explains the lack of association between the ROR score and benefit from chemotherapy in the overall population. Though the tumors with the lowest ROR are the luminal A subtype, with little sensitivity to chemotherapy, a large proportion of patients with basal-like breast cancer were assigned intermediate ROR scores and saw a large benefit from chemotherapy and most of the chemotherapy-insensitive Her2-enriched tumors were assigned high ROR scores. Consequently, within the overall population there is not a monotonic relationship between the ROR score and benefit from chemotherapy. However, when focusing on the ER+/Her2− population, we found a more direct relationship between risk and benefit from chemotherapy, although the analysis in this subset was not powered to show an interaction.

Our results are complementary to the results from the NCIC-CTG MA.5 trial, where all patients were treated with adjuvant chemotherapy but were randomized to CMF or CEF. Cheang and colleagues showed no added benefit in basal-like breast cancer but identified a substantial benefit in Her2-enriched high-risk breast cancer from the anthracycline-containing CEF chemotherapy as compared to CMF \[[@CR7]\]. The MA.5 and DBCG 89D trials and a pooled analysis with three additional phase III trials showed a greater benefit of anthracyclines in patients with *TOP2A* alterations and a trend towards greater benefit in patients with Her2-amplified tumors \[[@CR12]--[@CR15]\]. More recently, the DBCG READ trial gave no evidence to support a benefit from anthracyclines in patients with early *TOP2A*-normal breast cancer while the Anthracyclines in early breast cancer (ABC) trials suggested that patients with Her2-normal breast cancer derive some benefit from anthracyclines \[[@CR16], [@CR17]\]. The association between the Her2-enriched subtype and alteration of *TOP2A* has not yet been clarified but may improve the clinical utility of both markers. Finally, retrospective analyses of clinical studies in the metastatic setting have shown that the intrinsic subtype may predict benefit from other specific cytotoxic agents such as gemcitabine \[[@CR18]\] and docetaxel \[[@CR19]\]. Together these studies emphasize that the potential benefit to patients with breast cancer from establishing an association between intrinsic subtype and type of chemotherapy could be significant.

In this subset we showed a distribution of subtypes that differs from that previously demonstrated by immunohistochemical analysis (IHC) using tissue microarrays constructed from 633 patients participating in the DBCG 77B trial \[[@CR11]\]. The treatment effect appear less segregated between the luminal A and B subtypes using Prosigna compared to IHC, presumably due to the smaller percentage of luminal A tumors identified by the IHC definition employed in the previous study. In contrast, the effect obtained by an IHC definition of core-basal cancer was less pronounced compared to basal breast cancers as defined by Prosigna \[[@CR11]\]. While separate studies have shown that nucleic acid-based methods surpass the analytical reproducibility of IHC, our study confirms that genomic-based tests provide also additional information on clinical benefit compared to IHC surrogates \[[@CR20], [@CR21]\].

Due to the very old age of the DBCG77B study, we were only able to collect tumor blocks to be used for messenger (m)RNA testing from 623 of the original 1146 patients, and samples from the no chemotherapy arms (which were closed early and recruited smaller numbers of patients) were particularly sparse (Additional file [1](#MOESM1){ref-type="media"}: Figure S1), reducing study power compared to the original \[[@CR2]\] and even to subsequent IHC studies \[[@CR11]\] for which more cases were available. As a consequence, the ability to conduct subgroup analysis has been limited e.g. the possible influence of chemotherapy-induced amenorrhea, which may have been particularly important in patients with luminal cancers.

Beyond power concerns, this study has other potential limitations. First, the retrospective evaluation of only a subset of patients in the biomarker analysis introduces a risk of bias and a residual risk may persist despite adjustments in the multivariate analyses. Second, the 77B study samples analyzed here had been stored for almost 40 years resulting in significant degradation in the mRNA in the samples. This degradation was evident in the higher rate of samples that were unevaluable by the assay (22%) compared to 1% in a previous study using samples banked for a median of 10 years \[[@CR22]\]. DBCG77B only employed cyclophosphamide or classic CMF and benefit of a more pronounced effect could potentially have been obtained by more contemporary adjuvant chemotherapy. The contribution from cyclophosphamide might, however, have been inseparable from the contributions of anthracyclines, taxanes, endocrine therapy, and Her2-targeted therapy, if these treatments were combined. A possible association between molecular tumor subtype and the individual drugs may in later studies be obtained by identifying trials with successive addition of anthracyclines and taxanes.

Strengths of this study include use of patients with high-risk breast cancer derived from a phase III randomized trial without any biomarker selection. The inclusion of a control group who were not systemically treated was crucial for our ability to isolate associations between intrinsic subtypes by Prosigna and treatment effect from cyclophosphamide based-chemotherapy. In addition, our study adhered carefully to the ReMARK guidelines \[[@CR23]\], and used the validated and Food and Drug Association (FDA)-cleared Prosigna assay following standard operating procedures as specified by the manufacturer \[[@CR24]\].

Conclusions {#Sec10}
===========

In summary, this study demonstrates that the Prosigna assay is both prognostic and predictive of benefit from cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast cancer. These results provide further evidence that the high-risk intrinsic subtypes of breast cancer have highly differential responses to cyclophosphamide-based chemotherapy regimens, with clear benefit in the basal-like and luminal B subtypes.
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